Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b open-label study of ledipasvir/sofosbuvir with or without ribavirin in adults with chronic hepatitis C
2015-000690-13Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Mar 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of ledipasvir, sofosbuvir and ribavirin in chronic hepatitis C (CHC) (3 arms), sponsored by Gilead Sciences. Primary endpoint: SVR12. Started Mar 2015; status: completed.
02
Drugs
ledipasvirsofosbuvirribavirin
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2015-000690-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000690-13.